Roche Holding AG (OTCMKTS:RHHBY) Given Consensus Rating of “Hold” by Brokerages

Shares of Roche Holding AG (OTCMKTS:RHHBY) have received an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company.

RHHBY has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on Roche in a research note on Wednesday. They issued an “equal weight” rating for the company. Sanford C. Bernstein upgraded Roche to a “strong-buy” rating in a research note on Thursday, January 30th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Brooklyn Investment Group acquired a new stake in shares of Roche in the third quarter valued at $40,000. AlphaMark Advisors LLC acquired a new stake in shares of Roche in the third quarter valued at $149,000. IHT Wealth Management LLC acquired a new stake in shares of Roche in the third quarter valued at $236,000. Verity Asset Management Inc. bought a new position in Roche in the third quarter valued at about $253,000. Finally, Canopy Partners LLC boosted its holdings in Roche by 4.6% during the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after buying an additional 344 shares during the last quarter.

Roche Stock Down 1.1 %

Shares of OTCMKTS RHHBY opened at $39.43 on Wednesday. The business has a fifty day simple moving average of $36.70 and a 200 day simple moving average of $38.31. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche has a one year low of $29.20 and a one year high of $42.43.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.